Is it time for geriatricians to get on board with lecanemab? Jason Karlawish and Ken Covinsky
We’ve talked at length on prior podcasts about the failures of aducanumab, Biogen, and the FDA’s decision to approve it. …
We’ve talked at length on prior podcasts about the failures of aducanumab, Biogen, and the FDA’s decision to approve it. …
Eric and I weren’t sure what to call this podcast – storytelling and medicine? Narrative medicine? We discussed it with…
What would it take to transform dementia care? While a lot of hope and money is being put into new…
Assisted Living Communities (no longer preferable to call them Assisted Living Facilities, as we learned on the podcast) are…what, exactly? …
Health care professionals are human, and as humans we experience loss both in and out of work. You’d imagine though…
Dr. Faith Fitzgerald once quipped that prognostic modeling is the “punctilious quantification of the amorphous.” She has a point. Prognosis…
The Department of Health and Human Services helps to guide billions of dollars in investment and direction in research, policy,…
When I’m on service these days there is inevitably a moment when a resident says “Patient so-and-so is on X”…
Earlier this year palliative care was the correct response to the following clue on the game show Jeopardy: From a…
Have you had difficulty managing a particular type of cancer pain? For me it’s radiation induced mucositis/esophagitis. Janet Abrahm is…